Nurix Therapeutics, Inc. (NRIX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Nurix Therapeutics, Inc. presented at the RBC Capital Markets Global Healthcare Conference 2026. CEO Arthur Sands and Chief Business Officer Jason Kantor discussed their lead program, Bexdeg, and its potential advantages in treating chronic lymphocytic leukemia (CLL). The conference provided insights into the company's strategic direction and product development.
- ▪Nurix Therapeutics, Inc. participated in the RBC Capital Markets Global Healthcare Conference on May 20, 2026.
- ▪CEO Arthur Sands and CBO Jason Kantor represented the company during the event.
- ▪The discussion focused on their lead program, Bexdeg, and its potential benefits in the CLL treatment landscape.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4908140-nurix-therapeutics-inc-nrix-presents-at-rbc-capital-markets-global-healthcare-conference-2026"},"author":{"@type":"Person","name":"SA Transcripts","url":"https://seekingalpha.com/author/sa-transcripts"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New York","addressRegion":"NY","postalCode":"10001","addressCountry":"US"},"alternateName":["SeekingAlpha","SA"],"brand":[{"@type":"Brand","name":"Seeking Alpha Premium","url":"https://seekingalpha.com/subscriptions/premium"},{"@type":"Brand","name":"Seeking Alpha…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
